Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Receivables - Net (2023 - 2025)

Historic Receivables - Net for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Q2 2025 value amounting to $5.1 million.

  • Zhengye Biotechnology Holding's Receivables - Net changed N/A to $5.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.1 million, marking a year-over-year change of. This contributed to the annual value of $10.5 million for FY2024, which is 2023.69% down from last year.
  • According to the latest figures from Q2 2025, Zhengye Biotechnology Holding's Receivables - Net is $5.1 million.
  • In the past 5 years, Zhengye Biotechnology Holding's Receivables - Net ranged from a high of $12.9 million in Q4 2023 and a low of $5.1 million during Q2 2025
  • Moreover, its 3-year median value for Receivables - Net was $8.3 million (2024), whereas its average is $8.8 million.
  • Within the past 5 years, the most significant YoY rise in Zhengye Biotechnology Holding's Receivables - Net was 3565.15% (2024), while the steepest drop was 3565.15% (2024).
  • Quarter analysis of 3 years shows Zhengye Biotechnology Holding's Receivables - Net stood at $12.9 million in 2023, then tumbled by 35.65% to $8.3 million in 2024, then crashed by 38.41% to $5.1 million in 2025.
  • Its Receivables - Net stands at $5.1 million for Q2 2025, versus $8.3 million for Q4 2024 and $12.9 million for Q4 2023.